0RV2 Stock Chart & Stats
kr322.38
kr5.58(1.76%)
At close: 4:00 PM EDT
kr322.38
kr5.58(1.76%)
Day’s Range― - ―
52-Week Rangekr258.80 - kr364.40
Previous CloseN/A
Volume2.68K
Average Volume (3M)9.43K
Market Cap
kr28.87B
Enterprise Valuekr27.31K
Total Cash (Recent Filing)kr1.99B
Total Debt (Recent Filing)kr90.61M
Price to Earnings (P/E)278.2
Beta0.46
Next Earnings
Nov 25, 2026EPS Estimate
0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.19
Shares Outstanding74,324,486
10 Day Avg. Volume9,549
30 Day Avg. Volume9,430
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)13.99
Price to Sales (P/S)13.76
P/FCF Ratio19.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)3.17
Revenue Forecast (FY)kr1.36B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage reduces financial risk and interest burden, giving BioArctic greater flexibility to fund research, absorb development setbacks, and pursue partnerships without relying heavily on additional debt.
Strong Current ProfitabilityStrong current margins indicate that successful partnered programs can generate substantial economic value relative to operating costs, supporting internal funding capacity and resilience while the pipeline develops.
Positive Cash ConversionPositive operating and free cash flow provide funding for ongoing research and reduce dependence on external capital. Healthy current cash conversion also supports the company’s ability to manage long biotechnology development cycles.
Bears Say
Declining Revenue TrajectoryA sharply lower revenue run-rate weakens visibility into near-term operating scale and highlights the dependence on milestone, licensing, or partnered-product timing rather than a steadily expanding recurring revenue base.
High Earnings VolatilityLarge year-to-year earnings swings make underlying performance harder to forecast and may reflect irregular collaboration or milestone economics. This complicates long-term planning despite strong reported profitability in the latest period.
Inconsistent Free Cash FlowCash generation has not been consistently durable across reporting periods. Even with positive TTM free cash flow, sharp declines and prior negative years could constrain research investment if partnership receipts or milestones are delayed.
BioArctic AB Class B News
0RV2 FAQ
What was BioArctic AB Class B’s price range in the past 12 months?
BioArctic AB Class B lowest share price was kr258.80 and its highest was kr364.40 in the past 12 months.
What is BioArctic AB Class B’s market cap?
BioArctic AB Class B’s market cap is kr28.87B.
When is BioArctic AB Class B’s upcoming earnings report date?
BioArctic AB Class B’s upcoming earnings report date is Nov 25, 2026 which is in 88 days.
How were BioArctic AB Class B’s earnings last quarter?
BioArctic AB Class B released its earnings results on Aug 26, 2026. The company reported -kr0.13 earnings per share for the quarter, beating the consensus estimate of -kr0.335 by kr0.205.
Is BioArctic AB Class B overvalued?
According to Wall Street analysts BioArctic AB Class B’s price is currently Overvalued.
Does BioArctic AB Class B pay dividends?
BioArctic AB Class B does not currently pay dividends.
What is BioArctic AB Class B’s EPS estimate?
BioArctic AB Class B’s EPS estimate is 0.22.
How many shares outstanding does BioArctic AB Class B have?
BioArctic AB Class B has 74,324,486 shares outstanding.
What happened to BioArctic AB Class B’s price movement after its last earnings report?
BioArctic AB Class B reported an EPS of -kr0.13 in its last earnings report, beating expectations of -kr0.335. Following the earnings report the stock price went down -7.379%.
Which hedge fund is a major shareholder of BioArctic AB Class B?
Currently, no hedge funds are holding shares in GB:0RV2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioArctic AB Class B
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company’s therapeutic areas encompass neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is in phase 3 clinical trials; Lecanemab that is in back-up phase 3 clinical trials; Exidavnemab, which is in phase 2 clinical trials; Lecanemab, BAN2803, and BAN2802 that are in preclinical trials; and BAN1503, PD-BT2238, ND-BT3814, and GD-BT6822, which are in discovery stage. It has research collaboration agreements with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Technical Analysis
BioInvent International AB
―
Alzinova AB
―
AlzeCure Pharma AB
―
Saniona AB
―
IRLAB Therapeutics AB Class A
―